Article metrics
Thursday 06 October 2022 from 15:40 to 17:10
S11 immune system in SLE
S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study